期刊全稱 | Adalat | 期刊簡稱 | A Comprehensive Revi | 影響因子2023 | P. R. Lichtlen,A. Reale | 視頻video | http://file.papertrans.cn/145/144492/144492.mp4 | 圖書封面 |  | 影響因子 | As little as 30 years ago, cardiovascular research at Bayer was just a small sideline with in an environment dominated by chemotherapy research, and only 15 years ago, Bayer‘s pharmaceutical business was confined to European and Latin Ameri- can countries, with sales in cardiovascular pharmaceuticals close to zero. It goes without saying that Adalat has changed the company as a whole in its research, development, and marketing, both in Germany and, most importantly, world- wide. In research and development, Adalat has led the way in to new areas such as hypertension, acute neurology, dementia, atherosclerosis, and heart failure. In pharmacology, Adalat was present at the dawning of the second phar- macological revolution, which started out from whole animal models and progres- sed, via in vitro screening and pharmacological research on the DHP receptor, down to the molecular level with the cloning of calcium-channel proteins. Having followed the Adalat story closely in its early years as a bench scientist, let me take this opportunity to thank the inventors, the scientists, and the investigators who have helped to tap the broad potential of calcium-channel blockade with dihyd- ropy | Pindex | Conference proceedings 1991 |
The information of publication is updating
|
|